Biomedical literature, made navigable
Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsChoose an entity to see the articles in which it was identified.
…tervals than with previous anti-VEGF therapies, indicating that faricimab is effective for individualised dosing in real-world settings. …
…obtained an average score of 42.3, indicating a lower impact of haemophilia on daily life.Conclusion and Relevance Subcutaneous coagulation…
…n 14.9 g/L, elevated bilirubin, and liver enzyme abnormalities. Sirolimus 1 mg daily was initiated. After 5 days, the sirolimus trough le…
…Background and Importance Nivolumab was the first anti-PD-1 drug to be marketed, marking a signific…
…h anti-IL23-naïve individuals and those previously treated with Ustekinumab, in real-world clinical practice at a tertiary hospital.Materia…
…isease, and three with familial hypercholesterolaemia. Prior to inclisiran, 11 patients (28.9%) had been treated with evolocumab and 2 pat…
… patient restarted oral posaconazole and one patient changed to micafungin.From those patients who switched PAP to IV micafungin 3-4 mg/kg…
…64.4%) AT and 25 (55.6%) HP.The AT most frequently involved was paclitaxel (50; 11.3%), followed by cyclophosphamide (37; 8.4%), doxorubic…
…only suspected drugs were amoxicillin/clavulanate, amoxicillin, rivaroxaban, apixaban and ibuprofen; most frequent PT terms included allerg…
…kwave (€2,160 per device) exceeds the average GHS tariff, while Rotapro benefits from reimbursement through the List of Reimbursable Pr…
…heva D, et al. Genetic factors and risk of agranulocytosis from metamizole. Pharmacogenetics. 1996;6:67–72.4. Shah RR. Metamizole-induced …
…5:10.1038/s41375-024-02506-1.3. Dimopoulos MA, Moreau P, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32(3):3…